Modulation of haloperidol induced electrophysiological alterations on cardiac action potential by various risk factors and gender difference

Chemico-Biological Interactions

Volumn 180, Issue 3, 2009, Pages 454-459

  Raghu, K G ^a   Singh, Richa ^a   Prathapan, A ^b   Yadav, Govind Kumar ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

^b REGIONAL RESEARCH LABORATORY CSIR   (India)

Author keywords

Action potential; Haloperidol; Hypokalemia; Hypomagnesemia; Papillary muscle; Risk factors

Indexed keywords

ELECTROLYTE; HALOPERIDOL; ION CHANNEL; NEUROLEPTIC AGENT; SEX HORMONE;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ELECTROLYTE DISTURBANCE; FEMALE; GUINEA PIG; HEART ARRHYTHMIA; HEART ELECTROPHYSIOLOGY; HEART MUSCLE CONDUCTION DISTURBANCE; HEART MUSCLE ISCHEMIA; HEART MUSCLE POTENTIAL; HEART PACING; HEART PAPILLARY MUSCLE; HEART REPOLARIZATION; HUMAN; HYPOKALEMIA; HYPOMAGNESEMIA; MALE; MICROELECTRODE; NONHUMAN; QT PROLONGATION; REPERFUSION INJURY; RISK FACTOR; SEX DIFFERENCE;

ACTION POTENTIALS; ANIMALS; ANTIPSYCHOTIC AGENTS; ARRHYTHMIAS, CARDIAC; ELECTROLYTES; FEMALE; GONADAL STEROID HORMONES; GUINEA PIGS; HALOPERIDOL; ION CHANNELS; MALE; MICROELECTRODES; PAPILLARY MUSCLES; RISK FACTORS; SEX FACTORS;

CAVIA;

EID: 67349169048     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbi.2009.05.002     Document Type: Article

References (44)

1. Selzer A., and Wray H.W. Quinidine syncope: paroxysmal ventricular fibrillation occurring during treatment of chronic atrial arrhythmias. Circulation 30 (1964) 17-26
2. Lasser K.E., Allen P.D., Woolhandler S.J., Himmelstein D.U., Wolfe S.M., and Bor D.H. Timing of new black box warnings and withdrawals for prescription medications. JAMA 287 (2002) 2215-2220
3. Roden D.M. Drug-induced prolongation of the QT interval. N. Eng. J. Med. 350 (2004) 1013-1022
4. Dale K.M., Lertsburapa K., Kluger J., and White C.M. Moxifloxacin and torsade de pointes. Ann. Pharmacother. 41 (2007) 336-340
5. Aktas M.K., Shah A.H., and Akiyama T. Dofetilide-induced long QT and torsades de pointes. Ann. Noninvasive Electrocardiol. 12 (2007) 197-202
6. Isbister G.K., Murray L., John S., Hackett L.P., Haider T., O' Mullane P., Gosselin S., and Daly F. Amisulpride deliberate self-poisoning causing severe cardiac toxicity including QT prolongation and torsades de pointes. Med. J. 184 (2006) 354-356
7. Hancox J.C., and Mitcheson J.S. Combined hERG channel inhibition and disruption of trafficking in drug-induced long QT syndrome by fluoxetine: a case-study in cardiac safety pharmacology. Br. J. Pharmacol. 149 (2006) 457-459
8. Aypar E., Karagoz A.H., Ozer S., Celiker A., and Ocal T. The effects of sevoflurane and desflurane anesthesia on QTc interval and cardiac rhythm in children. Paediatr. Anaesth. 17 (2007) 563-567
9. Fayer S.A. Torsades de pointes ventricular tachyarrhythmia associated with haloperidol. J. Clin. Psychopharmacol. 6 (1986) 375-376
10. Henderson R.A., Lane S., and Henry J.A. Life-threatening ventricular arrhythmia (torsades de pointes) after haloperidol overdose. Hum. Exp. Toxicol. 10 (1991) 59-62
11. Metzger E., and Friedman R. Prolongation of the corrected QT and torsades de pointes cardiac arrhythmia associated with intravenous haloperidol in the medically ill. J. Clin. Psychopharmacol. 13 (1993) 128-132
12. Hunt N., and Stern T.A. The association between intravenous haloperidol and Torsades de Pointes. Three cases and a literature review. Psychosomatics 36 (1995) 541-549
13. Champeroux P., Viaud K., El Amrani A.I., Fowler J.S., Martel E., Le Guennec J.Y., and Richard S. Prediction of the risk of Torsade de Pointes using the model of isolated canine Purkinje fibres. Br. J. Pharmacol. 144 (2005) 376-385
14. Justo D., Prokhorov V., Heller K., and Zeltser D. Torsade de pointes induced by psychotropic drugs and the prevalence of its risk factors. Acta Psychiatr. Scand. 111 (2005) 171-176
15. Merri M., Benhorin J., Alberti M., Locati E., and Moss A.J. Electrocardiographic quantization of ventricular repolarization. Circulation 80 (1989) 1301-1308
16. Rautaharju P.M., Zhou S.H., Wong S., Calhoun H.P., Berenson G.S., Prineas R., and Davignon A. Sex differences in the evolution of the electrocardiographic QT interval with age. Can. J. Cardiol. 8 (1992) 690-695
17. Makkar R.R., Fromm B.S., Steinman R.T., Meissner M.D., and Lehmann M.H. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA 270 (1993) 2590-2597
18. Drici M.D., Burklow T.R., Haridasse V., Glazer R.I., and Woosley R.L. Sex hormones prolong the QT interval and down regulate potassium channel expression in the rabbit heart. Circulation 94 (1996) 1471-1474
19. Antzelevitch C., Sherif N., Rosenbaum D., and Vos M. Cellular mechanisms underlying the long QT syndrome. J. Cardiovasc. Electrophysiol. 14 (2003) 114-115
20. Yan G.X., Joshi A., Guo D., Hlaing T., Martin J., Xu X., and Kowey P.R. Phase 2 reentry as a trigger to initiate ventricular fibrillation during early acute myocardial ischemia. Circulation 110 (2004) 1036-1041
21. Viswanathan P.C., and Rudy Y. Pause induced early after depolarizations in the long QT syndrome: a simulation study. Cardiovasc. Res. 42 (1999) 530-542
22. Luo C.H., and Rudy Y. A dynamic model of the cardiac ventricular action potential. I. Simulations of ionic currents and concentration changes. Circ. Res. 74 (1994) 1071-1096
23. Lu H.R., Vlaminckx E., Van Ammel K., and De Clerck F. Drug-induced long QT in isolated rabbit Purkinje fibers: importance of action potential duration, triangulation and early after depolarizations. Eur. J. Pharmacol. 452 (2002) 183-192
24. Rials S.J., Wu Y., Xu X., Filart R.A., Marinchak R.A., and Kowey P.R. Regression of left ventricular hypertrophy with captopril restores normal ventricular action potential duration, dispersion of refractoriness, and vulnerability to inducible ventricular fibrillation. Circulation 96 (1997) 1330-1336
25. Boutjdir M., Restivo M., Wei Y., Stergiopoulos K., and el-Sherif N. Early after depolarization formation in cardiac myocytes: analysis of phase plane patterns, action potential, and membrane currents. J. Cardiovasc. Electrophysiol. 5 (1994) 609-620
26. Khan I.A. Clinical and therapuetic aspects of congenital and acquired long QT syndrome. Am. J. Med. 42 (2002) 55-56
27. Poelzing S., and Veeraraghavan R. Heterogeneous ventricular chamber response to hypokalemia and inward rectifier potassium channel blockade underlies bifurcated T wave in guinea pig. Am. J. Physiol. 292 (2007) 3043-3051
28. Gautam M., Dixit C., Singh S., Tewari A., Raghu K.G., Prakash P., and Tripathi O. Frequency and time dependent effect of fendiline on action potential of G. pig papillary muscle. Jpn. J. Pharmacol. 83 (2000) 175-181
29. Tsujimae K., Suzuki S., Murakami S., and Kurachi Y. Frequency-dependent effects of various IKr blockers on cardiac action potential duration in a human atrial model. Am. J. Physiol. Heart Circ. Physiol. 293 (2007) 660-669
30. Hondeghem L.M., Dujardin K., and De Clerck F. Phase 2 prolongation, in the absence of instability and triangulation, antagonizes class III proarrhythmia. Cardiovasc. Res. 50 (2001) 345-353
31. Furushima H., Niwano S., Chinushi M., Ohhira K., Abe A., and Aizawa Y. Relation between bradycardia dependent long QT syndrome and QT prolongation by disopyramide in humans. Heart 79 (1998) 56-58
32. Haverkamp W., and Deuschle M. Lengthening of QT interval by antipsychotic drugs. Nervenarzt 77 (2006) 276-284
33. Reingardiene D., and Vilcinskaitė J. QTc-prolonging drugs and the risk of sudden death. Medicina (Kaunas) 43 (2007) 347-353
34. Dhein S., Perlitz F., and Mohr F.W. An in vitro model for assessment of drug-induced torsade de pointes arrhythmia: effects of haloperidol and dofetilide on potential duration, repolarization inhomogeneities, and torsade de pointes arrhythmia. Naunyn Schmiedebergs Arch. Pharmacol. 378 (2008) 631-644
35. Terrar D.A., Wilson C.M., Graham S.G., Bryant S.M., and Heath B.M. Comparison of guinea-pig ventricular myocytes and dog Purkinje fibres for in vitro assessment of drug-induced delayed repolarization. J. Pharmacol. Toxicol. Methods 56 (2007) 171-185
36. Limberis J.T., McDermott J.S., Salmen H.J., Su Z., Mikhail A., Green J.R., Cox B.F., Gintant G.A., and Martin R.L. The effects of plasma proteins on delayed repolarization in vitro with cisapride, risperidone, and D,L-sotalol. J. Pharmacol. Toxicol. Methods 56 (2007) 11-17
37. Drolet B., Zhang S., Deschenes D., Rail J., Nadeau S., Zhou Z., January C.T., and Turgeon J. Droperidol lengthens cardiac repolarization due to block of the rapid component of the delayed rectifier potassium current. J. Cardiovasc. Electrophysiol. 10 (1999) 1597-1604
38. Michailova A.P., Belik M.E., and Mc Culloch A.D. Effect of magnesium on cardiac excitation contraction coupling. J. Am. Coll. Nutr. 23 (2004) 514-517
39. Hondeghem L.M., and Snyders D.J. Class III antiarrhythmic agents have a lot of potential but a long way to go. Reduced effectiveness and dangers of reverse use dependence. Circulation 81 (1990) 686-690
40. Kr. Circulation 93 (1996) 407-411
41. Elming H., Sonne J., and Lublin H.K. The importance of the QT interval: a review of the literature. Acta Psychiatr. Scand. 107 (2003) 96-101
42. Manning A.S., and Hearse D.J. Reperfusion-induced arrhythmias: mechanisms and prevention. J. Mol. Cell. Cardiol. 16 (1984) 497-518
43. Pogwizd S.M., and Corr P.B. Electrophysiologic mechanisms underlying arrhythmias due to reperfusion of ischemic myocardium. Circulation 76 (1987) 404-426
44. + currents of canine Purkinje fibre cardiac action potential: key roles for IKs, beta-adrenoceptor stimulation, pacing rate and gender. Br. J. Pharmacol. 147 (2006) 653-660